Putnam Investments LLC Sells 562 Shares of Humana Inc (HUM)

Putnam Investments LLC lowered its stake in Humana Inc (NYSE:HUM) by 0.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 223,337 shares of the insurance provider’s stock after selling 562 shares during the period. Putnam Investments LLC owned approximately 0.16% of Humana worth $75,604,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Sio Capital Management LLC boosted its position in shares of Humana by 12.7% during the third quarter. Sio Capital Management LLC now owns 20,054 shares of the insurance provider’s stock valued at $6,789,000 after buying an additional 2,261 shares during the period. Worldquant Millennium Quantitative Strategies LLC boosted its position in shares of Humana by 3.5% during the third quarter. Worldquant Millennium Quantitative Strategies LLC now owns 61,044 shares of the insurance provider’s stock valued at $20,665,000 after buying an additional 2,044 shares during the period. EP Wealth Advisors LLC boosted its position in shares of Humana by 21.4% during the third quarter. EP Wealth Advisors LLC now owns 929 shares of the insurance provider’s stock valued at $314,000 after buying an additional 164 shares during the period. Verition Fund Management LLC boosted its position in shares of Humana by 457.0% during the third quarter. Verition Fund Management LLC now owns 4,523 shares of the insurance provider’s stock valued at $1,531,000 after buying an additional 3,711 shares during the period. Finally, Pacer Advisors Inc. boosted its position in shares of Humana by 16.6% during the third quarter. Pacer Advisors Inc. now owns 7,546 shares of the insurance provider’s stock valued at $2,554,000 after buying an additional 1,076 shares during the period. Institutional investors own 92.71% of the company’s stock.

Several brokerages have issued reports on HUM. Zacks Investment Research upgraded Humana from a “hold” rating to a “buy” rating and set a $350.00 target price for the company in a research report on Friday. ValuEngine lowered Humana from a “buy” rating to a “hold” rating in a research report on Friday, December 7th. Morgan Stanley boosted their target price on Humana from $400.00 to $418.00 and gave the company a “buy” rating in a research report on Thursday, November 8th. BMO Capital Markets set a $390.00 target price on Humana and gave the company a “buy” rating in a research report on Thursday, November 8th. Finally, Royal Bank of Canada boosted their target price on Humana from $318.00 to $349.00 and gave the company a “sector perform” rating in a research report on Thursday, November 8th. Seven analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $350.95.

In related news, insider Roy A. Beveridge sold 4,622 shares of the business’s stock in a transaction that occurred on Thursday, November 8th. The stock was sold at an average price of $341.06, for a total value of $1,576,379.32. Following the completion of the sale, the insider now owns 10,621 shares in the company, valued at $3,622,398.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.60% of the stock is currently owned by insiders.

Shares of NYSE HUM opened at $299.93 on Friday. The company has a quick ratio of 1.68, a current ratio of 1.68 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $41.15 billion, a P/E ratio of 25.61, a PEG ratio of 1.42 and a beta of 0.99. Humana Inc has a 52-week low of $242.00 and a 52-week high of $355.88.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, November 7th. The insurance provider reported $4.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.29 by $0.29. The firm had revenue of $14.21 billion during the quarter, compared to analyst estimates of $13.97 billion. Humana had a return on equity of 19.10% and a net margin of 2.70%. During the same quarter in the previous year, the business earned $3.39 earnings per share. Analysts anticipate that Humana Inc will post 14.43 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, January 25th. Investors of record on Monday, December 31st will be issued a $0.50 dividend. The ex-dividend date is Friday, December 28th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 0.67%. Humana’s payout ratio is 11.96%.

COPYRIGHT VIOLATION WARNING: This piece of content was first reported by WKRB News and is the sole property of of WKRB News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.wkrb13.com/2018/12/16/putnam-investments-llc-sells-562-shares-of-humana-inc-hum.html.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

See Also: Calculate Your Return on Investment (ROI)

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply